Olanzapine Versus Aripiprazole in the Treatment of Acutely Ill Patients With Schizophrenia

Eli Lilly and Company600 enrolled

Overview

The purposes of this study are to assess similarities and differences in the efficacy (how well the drug works), safety, and side effects of olanzapine and aripiprazole in patients with schizophrenia, schizoaffective disorder, or schizophreniform disorder.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

600

Conditions

Schizophrenia

Interventions

OlanzapineDRUG

AripiprazoleDRUG

Eligibility

Sex: ALLMin age: 18 YearsMax age: 55 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients must have schizophrenia, schizoaffective disorder, or schizophreniform disorder * Patients must be agitated * Patients must display psychotic symptoms * Patients must be inpatients who are expected to stay in the hospital for at least 5 days * Patients must be 18 to 55 years of age Exclusion Criteria: * Patients may not be hospitalized for greater than 72 hours prior to study start * Patients may not have received more than one dose of olanzapine or aripiprazole within 72 hours prior to study start * Patients may not be actively suicidal * Patients may not be diagnosed with substance-induced psychosis or substance dependence * Patients may not have acute, serious, or unstable medical conditions

Locations (5)

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. test

Saint Charles, Missouri, United States

Beachwood, Ohio, United States

Outcomes

Primary Outcomes

The primary objective of this study is to test the hypothesis that olanzapine is superior to aripiprazole in the reduction of symptoms of agitation in acutely ill patients with schizophrenia, as measured by mean change in the

Positive and Negative Syndrome Scale Excited Component (PANSS-EC) over 5 days of treatment (4 continuous 24 hr treatment exposures). The null hypothesis of the study is that there is no difference between olanzapine and

aripiprazole in reducing agitation.

Secondary Outcomes

The reduction in positive symptoms as measured by the Brief Psychiatric Rating Scale Positive subscale (PBRS Positive);

The reduction of symptoms of agitation as measured by Overt Agitation Severity Scale (OASS);

The proportion of patients responding to treatment and the time to response based on varying levels in the percent reduction of

the PANSS_EC from baseline;

The reduction in overall severity of psychiatric illness as measured by the Clinical Global Impression-Severity Scale (CGI-S);

The intensity of nursing intervention (e.g. seclusion, restraint, special nursing watch), as measured by the Global Assessment

of Nursing Intervention

The proportion of patients using pm lorazepam and the time-course of usage.

The proportion of patients discontinuing from the study due to lack of efficacy or due to adverse events related to worsening

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.